Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock

Key Points

• COO Ryan Cohlhepp sold 18,750 BCAX shares for $524,625 under a pre-arranged Rule 10b5-1 plan, reducing his position by 9.36% to 181,641 shares.
• Bicara Therapeutics’ stock rose 3.7% to $24.63, while the company reported a quarterly loss of $0.82 per share, in line with analyst expectations.
• Analyst sentiment remains mixed but generally positive: the consensus rating is “Moderate Buy” with a $32.73 average price target, while targets range from $23 at Wells Fargo to $39 at BTIG.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 18,750 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $524,625.00. Following the completion of the transaction, the chief operating officer owned 181,641 shares in the company, valued at approximately $5,082,315.18. The trade was a 9.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total value of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total value of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total value of $253,625.00.

Bicara Therapeutics Stock Up 3.7%

Bicara Therapeutics stock traded up $0.87 during mid-day trading on Wednesday, hitting $24.63. The company had a trading volume of 810,259 shares, compared to its average volume of 608,476. Bicara Therapeutics Inc. has a 1 year low of $10.30 and a 1 year high of $30.99. The business has a fifty day moving average of $25.90 and a 200 day moving average of $21.69. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -8.86 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). Equities analysts anticipate that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BCAX. Legal & General Group Plc raised its stake in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after buying an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics during the 4th quarter worth $45,000. Larson Financial Group LLC lifted its stake in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after acquiring an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BCAX. Wells Fargo & Company raised their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a report on Wednesday. BTIG Research upped their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the company a "buy" rating in a research report on Wednesday. Mizuho raised their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $32.73.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source